Basal characteristics of the 104 patients who experienced COVID-19 were compared with those of 154 patients who did not experience the infection
| . | Patients with COVID-19 (n = 104) . | Patients without COVID-19 (n = 154) . | P value . |
|---|---|---|---|
| Age, Med (95% CI) | 69 (66-70) | 71 (68-71) | .222 |
| Sex, M | 69.2% | 71.4% | .704 |
| CIRS, Med | 4 (3-5) | 5 (4-6) | .502 |
| Smoking, yes | 14.6% | 19.5% | .309 |
| Diabetes, yes | 7.7% | 13.6% | .138 |
| COPD, yes | 15.4% | 13.6% | .694 |
| CrCl <70 mL/min, yes | 36.5% | 40.1% | .562 |
| Previous lines of treatment, Med | 1 (1-2) | 2 (2-2) | .020 |
| Previous infection, yes | 21.1% | 37.7% | .005 |
| Previous pneumonia, yes | 7.7% | 9.8% | .571 |
| Previous COVID-19, yes | 4.1% | 5.2% | .695 |
| Association to anti-CD20, yes | 64.4% | 44.8% | .002 |
| Immunoglobulin prophylaxis, yes | 16.4% | 22.1% | .256 |
| PJP prophylaxis, yes | 60.6% | 56.5% | .514 |
| Antiviral prophylaxis, yes | 35.6% | 40.9% | .388 |
| RAI III-IV, yes | 50.9% | 46.1% | .443 |
| IGHV, unmut | 70.8% | 70.9% | .987 |
| Del17, yes | 26.6% | 31.8% | .379 |
| TP53, yes | 26.6% | 36.4% | .121 |
| Del11, yes | 19.4% | 26.9% | .178 |
| Tri12, yes | 10.2% | 15.6% | .229 |
| Del13, yes | 27.6% | 38.9% | .065 |
| IgG, Med | 585 (472-679) | 600 (551-650) | .923 |
| LDH above ULN, yes | 47.6% | 45.5% | .749 |
| . | Patients with COVID-19 (n = 104) . | Patients without COVID-19 (n = 154) . | P value . |
|---|---|---|---|
| Age, Med (95% CI) | 69 (66-70) | 71 (68-71) | .222 |
| Sex, M | 69.2% | 71.4% | .704 |
| CIRS, Med | 4 (3-5) | 5 (4-6) | .502 |
| Smoking, yes | 14.6% | 19.5% | .309 |
| Diabetes, yes | 7.7% | 13.6% | .138 |
| COPD, yes | 15.4% | 13.6% | .694 |
| CrCl <70 mL/min, yes | 36.5% | 40.1% | .562 |
| Previous lines of treatment, Med | 1 (1-2) | 2 (2-2) | .020 |
| Previous infection, yes | 21.1% | 37.7% | .005 |
| Previous pneumonia, yes | 7.7% | 9.8% | .571 |
| Previous COVID-19, yes | 4.1% | 5.2% | .695 |
| Association to anti-CD20, yes | 64.4% | 44.8% | .002 |
| Immunoglobulin prophylaxis, yes | 16.4% | 22.1% | .256 |
| PJP prophylaxis, yes | 60.6% | 56.5% | .514 |
| Antiviral prophylaxis, yes | 35.6% | 40.9% | .388 |
| RAI III-IV, yes | 50.9% | 46.1% | .443 |
| IGHV, unmut | 70.8% | 70.9% | .987 |
| Del17, yes | 26.6% | 31.8% | .379 |
| TP53, yes | 26.6% | 36.4% | .121 |
| Del11, yes | 19.4% | 26.9% | .178 |
| Tri12, yes | 10.2% | 15.6% | .229 |
| Del13, yes | 27.6% | 38.9% | .065 |
| IgG, Med | 585 (472-679) | 600 (551-650) | .923 |
| LDH above ULN, yes | 47.6% | 45.5% | .749 |
CI, confidence interval; CIRS, Cumulative Illness Rating Scale; COPD, Chronic Obstructive Pulmonary Disease; CrCl, Creatinine Clearance; IgG, immunoglobulin G; IGHV, immunoglobulin heavy chain variable; LDH, lactate dehydrogenase; M, male; Med, median; PJP, Pneumocystis jiroveci pneumonia; ULN, upper limit of normal; unmut, unmutated.